Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 15/20 | 0.49 |
| ▸ | ITGA4 | P13612 | 15/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2058944 | 0.88 | ITGB1 (0.63) | ITGB1ITGA4 | |
| SCHEMBL2058768 | 0.85 | ITGB1 (0.50) | ITGB1ITGA4MMP9C5AR1LMNA | |
| SCHEMBL3936071 | 0.83 | KEAP1 (0.45) | ITGB1ITGA4MMP9C5AR1LMNA | |
| SCHEMBL2058599 | 0.81 | ITGB1 (0.63) | ITGB1ITGA4 | |
| SCHEMBL2059158 | 0.78 | ITGB1 (0.52) | ITGB1ITGA4 | |
| SCHEMBL2059087 | 0.78 | ITGB1 (0.71) | ITGB1ITGA4 | |
| SCHEMBL2058929 | 0.77 | ITGB1 (0.51) | ITGB1ITGA4 | |
| SCHEMBL3936177 | 0.76 | ITGB1 (0.55) | ITGB1ITGA4 | |
| SCHEMBL4449774 | 0.74 | ITGB1 (0.60) | ITGB1ITGA4 | |
| SCHEMBL2059117 | 0.73 | ITGB1 (0.54) | ITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1635822-A4 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | ELAN PHARM INC (US) | 2009-06-24 | — | — | EP | claimed |
| JP-2007526230-A | — | — | 2007-09-13 | — | — | JP | claimed |
| EP-1635822-A2 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | Elan Pharmaceuticals, Inc. (US) | 2006-03-22 | — | — | EP | claimed |
| US-20050203093-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS | 2005-09-15 | — | — | US | claimed |
| US-20050065192-A1 | Methods and compositions for treating rheumatoid arthritis | ELAN PHARMACEUTICALS, INC. (US) | 2005-03-24 | — | — | US | claimed |
| WO-2005000246-A2 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | ELAN PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | WO | claimed |
| US-20040147512-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | claimed |
| US-20030139402-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated byVLA-4 | KONRADI ANDREI W (US) | 2003-07-24 | — | — | US | claimed |
| US-20030125324-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | KONRADI ANDREI W (US) | 2003-07-03 | — | — | US | claimed |
| EP-1144388-A1 | ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS | Elan Pharmaceuticals, Inc. (US) | 2001-10-17 | — | — | EP | claimed |
| WO-2000043372-A1 | ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS | ELAN PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | claimed |
| US-7973044-B2 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7968547-B2 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-20100160343-A1 | HETEROARYL, HETEROCYCLIC AND ARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. | 2010-06-24 | — | — | US | disclosed |
| US-20100160341-A1 | HETEROARYL, HETEROCYCLIC AND ARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. | 2010-06-24 | — | — | US | disclosed |
| US-20030139402-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated byVLA-4 | KONRADI ANDREI W (US) | 2003-07-24 | — | — | US | disclosed |
| US-20030125324-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | KONRADI ANDREI W (US) | 2003-07-03 | — | — | US | disclosed |
| US-6492372-B1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. | 2002-12-10 | — | — | US | disclosed |
| EP-1144388-A1 | ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS | Elan Pharmaceuticals, Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000043372-A1 | ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS | ELAN PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139402-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated byVLA-4 | VCAM1, ICAM1, ITGB4 | ITGB1 46/4885ITGA4 5/4885MMP9 1737/4885 |
| US-20100160341-A1 | HETEROARYL, HETEROCYCLIC AND ARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | VCAM1, ICAM1, ITGB4 | ITGB1 29/4885ITGA4 7/4885MMP9 1453/4885 |
| US-20030125324-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, ITGB4 | ITGB1 29/4885ITGA4 7/4885MMP9 1453/4885 |
| US-20050203093-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, ITGB4 | ITGB1 29/4885ITGA4 7/4885MMP9 1453/4885 |
| US-20040147512-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, ITGB4 | ITGB1 29/4885ITGA4 7/4885MMP9 1453/4885 |
| US-20050065192-A1 | Methods and compositions for treating rheumatoid arthritis | VCAM1, ICAM1, ITGA4 | ITGB1 8/4885ITGA4 3/4885MMP9 225/4885 |
| US-20100160343-A1 | HETEROARYL, HETEROCYCLIC AND ARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | VCAM1, ICAM1, ITGB4 | ITGB1 29/4885ITGA4 7/4885MMP9 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.